Meridian Wealth Management’s ADMA Biologics ADMA Stock Holding History

Meridian Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,000	Closed	-$66K	–	547
2022 Q4	$66K	Sell	17,000 -33,000	-66%	-$102K	0.01%	515
2022 Q3	$122K	Sell	50,000 -30,000	-38%	-$72K	0.01%	469
2022 Q2	$158K	Sell	80,000 -70,000	-47%	-$138K	0.01%	520
2022 Q1	$275K	Hold	150,000	–	–	0.03%	328
2021 Q4	$212K	Sell	150,000 -56,000	-27%	-$73.6K	0.02%	376
2021 Q3	$233K	Buy	206,000 +42,000	+26%	+$58.8K	0.03%	355
2021 Q2	$262K	Buy	164,000 +64,000	+64%	+$113K	0.03%	321
2021 Q1	$176K	Hold	100,000	–	–	0.03%	354
2020 Q4	$195K	Buy	100,000 +40,000	+67%	+$84.1K	0.03%	322
2020 Q3	$143K	Buy	60,000 +40,000	+200%	+$110K	0.04%	246
2020 Q2	$58K	Buy	+20,000	New	+$57.5K	0.02%	222

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Meridian Wealth Management's ADMA Position: Q1 2023 in Review

Meridian Wealth Management sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 17,000 shares — an estimated $66K sold.

Meridian Wealth Management first reported a position in ADMA in Q2 2020 and held it in 11 quarters. The position peaked at $275K in Q1 2022. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

Meridian Wealth Management reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
Meridian Wealth Management sold 17,000 ADMA Biologics shares in Q1 2023, an estimated $66K.
Meridian Wealth Management first reported a position in ADMA Biologics in Q2 2020 and held it in 11 quarters.
Meridian Wealth Management's ADMA Biologics position peaked at $275K in Q1 2022.
163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Meridian Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.